MedTrace Logo

Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains

NCT02855229 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2024-10-30

No results posted yet for this study

Summary

The overarching goal of this multi-disciplinary research program is to develop and optimize new cross-species translational assessments of reward and cognition that will not only be assessed in parallel in humans and rats, but also produce neurophysiological and behavioral metrics that can be objectively compared across species. The research will build on prior studies by further developing and optimizing (in Phase 1), then validating via pharmacological challenge (in Phase 2), the following assays in both humans and rats:

1. advanced neurophysiological and computational modeling techniques to record and analyze EEG activity within and across species; and
2. behavioral assessments of reward learning, cognitive control, and cognitive flexibility will be analyzed within and across species.

The second phase of the study will test the translational validity of these assays, by assessing the impact of a targeted drug on task performance and EEG activity in both species.

Conditions

  • Translational Electrophysiology

Interventions

DRUG

Methylphenidate

cross-over, single-dose intervention

Sponsors & Collaborators

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • Diego A Pizzagalli, PhD · Mclean Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-15
Primary Completion
2021-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02855229 on ClinicalTrials.gov